GBT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GBT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Global Blood Therapeutics's Dividends per Share for the three months ended in Jun. 2022 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
Global Blood Therapeutics's Dividend Payout Ratio for the three months ended in Jun. 2022 was 0.00. As of today, Global Blood Therapeutics's Dividend Yield % is 0.00%.
For more information regarding to dividend, please check our Dividend Page.
For the Biotechnology subindustry, Global Blood Therapeutics's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's 5-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Global Blood Therapeutics's 5-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
Global Blood Therapeutics (NAS:GBT) 5-Year Dividend Growth Rate Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Global Blood Therapeutics's Dividend Payout Ratio for the quarter that ended in Jun. 2022 is calculated as
Dividend Payout Ratio | = | Dividends per Share (Q: Jun. 2022 ) | / | EPS without NRI (Q: Jun. 2022 ) |
= | 0 | / | -1.26 | |
= | N/A |
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Global Blood Therapeutics's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey S Farrow | officer: Chief Financial Officer | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Nazila Habibizad | officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Philip A. Pizzo | director | ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Carrie Krehlik | officer: Chief Human Resources Officer | 6015 COLTON BLVD, OAKLAND CA 94611 |
Eric Fink | officer: Chief Human Resources Officer | C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 |
Kim Smith-whitley | officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 |
Alexis A. Thompson | director | C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 |
Brian Edwin Cathers | officer: Chief Scientific Officer | C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 |
Lesley Ann Calhoun | officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Mark L Perry | director | 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941 |
Ted W Love | director, officer: See Remarks | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Tricia Borga Suvari | officer: Chief Legal Officer | 3172 PORTER DRIVE PALO ALTO CA 94034 |
Brown Willie L. Jr. | director | C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 07-15-2022
By Ds*** Ds*** • 08-31-2022
By PurpleRose PurpleRose • 07-13-2022
By GuruFocus Research GuruFocus Editor • 02-18-2023
By PurpleRose PurpleRose • 08-09-2022
By PurpleRose PurpleRose • 07-11-2022
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 08-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.